TCTMD’s Top 10 Most Popular Stories for November 2017

The ORBITA study was the hands-down winner for top story this month, but our story on the new hypertension guidelines was also a top contender.

TCTMD’s Top 10 Most Popular Stories for November 2017

The ORBITA study, presented at TCT 2017, was the hands-down winner for top story in November, but the new hypertension guidelines, released just a week and a half later at the American Heart Association (AHA) 2017 Scientific Sessions, also were a top contender. Other big studies from both meetings round out the list, including DAPT-STEMI and REDUCE, FAME 2 at 3 years, and CULPRIT-SHOCK

ORBITA: PCI Offers No Symptom Improvement Over Sham Procedure

The intriguing study, which hinted at a placebo effect of PCI, left physicians debating the merits of revascularization in stable coronary artery disease.

Long-Awaited Hypertension Guidelines Released at AHA

The treatment goal has been lowered, and a new classification expands the number of US adults considered to have hypertension.

Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES

DAPT-STEMI and REDUCE found 3 and 6 months of DAPT, respectively, were noninferior to the standard 12 months of treatment.

FAME 2 at 3 Years: Outcomes, Symptoms Better With PCI vs OMT in Stable CAD, at Similar Cost

The study found strikingly fewer urgent revascularizations and numerically fewer deaths and MIs in the PCI group when fractional flow reserve was gatekeeper.

CULPRIT-SHOCK Disputes Benefit of Immediate Multivessel PCI in Patients With Cardiogenic Shock

The results, which challenge current guidelines and appropriate use criteria, will change practice, several experts agreed.

Long-term Absorb BVS Data Continue to Disappoint

While two analyses suggest the thrombotic risk can be mitigated, others say the data are “frustrating” in that there’s still not even a hint of benefit.

DES With Bioresorbable Polymer Outperforms BMS in SENIOR Patients

A chorus of interventionalists all agreed that BMS have an extremely limited role, if any, in clinical practice following results of several studies.

RECAP: In the Cath Lab, a Lead-free Pad Placed on the Patient Cuts Operator Radiation Exposure

This is an important, rigorously conducted study in an area that is sorely in need of good data, Sunil Rao says.

Longer-term Outcomes of Watchman Reassure as Debate Continues Over How It Should Be Used

Lingering questions about the potential for residual ischemic stroke risk with the LAA closure device temper enthusiasm for its use.


Features and Opinion

Beyond the news, there was plenty of noteworthy editorial content in other sections of the site.

FEATURE: Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

OPINION: My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

VIDEO: On Record: All Eyes on ORBITA

FEATURE: Conference Organizers, Physicians Wary as Direct Industry Sponsorship Winds Down in Europe

We Recommend